Adjuvant nivolumab data published in NEJM show DFS benefit in bladder cancer
The published data are from the pivotal CheckMate 274 trial and are currently being reviewed by the FDA for a potential approval of nivolumab in this setting.
Related Articles
Dr. Morgan on the evolving field of salvage therapy in prostate cancer
“I think that this field is going to continue to evolve, especially when we think about how to incorporate PSMA-PET findings into our clinical care,”…
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further…
Integration of family history, germline genetics is important in defining prognosis of prostate cancer
“I think the greatest implication the study has is that it tells us that family history and germline genetics independently provide complementary information that’s important…
18-gene urine test may reduce unnecessary prostate biopsies
The MPS2 models demonstrated negative predictive values of 95% to 99% for cancers of grade group 2 or higher and of 99% for cancers of…
Dr. Goudelocke outlines stand-up urgency in patients with OAB
“There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they…
Future work in urology may look at factors influencing pursuit of the field
“We can also look at the timing of exposure to urology. Does early exposure spark interest in urology, or does delayed introduction to the field…
Study launches of CAR T therapy for bone metastatic prostate cancer
“We are hopeful that this therapy will help patients with prostate cancer and that this study will be just the first step towards the effective…
Expert discusses meta-analysis of prostate radiotherapy
“In my view, at present in patients that have low-volume oligometastatic de novo metastatic prostate cancer, it’s really an unknown whether comprehensive SBRT or other…
UTv Videos
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Study finds disparities in management of mCSPC
“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for…